◀ Back to TP53

EP300 — TP53

Pathways - manually collected, often from reviews:

• OpenBEL Selventa BEL large corpus: TP53 → EP300 (directlyIncreases, EP300 Activity)
  Evidence: P300 coactivates P53-activated promotors, including p21, Bax, and Mdm2. P300 binds the transactivation domain in the Nterminal region of p53 - this interaction is involved in the coactivation of p53 by p300
• BioCarta hypoxia and p53 in the cardiovascular system: TFIID/RPA/JNK/p300/p53 complex (TAF1-RPA1-MAPK8-EP300-TP53) → Mdr1b (ABCB1) (transcription, activates)
• BioCarta hypoxia and p53 in the cardiovascular system: TFIID/RPA/JNK/p300/p53 complex (TAF1-RPA1-MAPK8-EP300-TP53) → BAX (transcription, activates)
• BioCarta cell cycle: g2/m checkpoint: p53 (TP53) → p300 (EP300) (transcription, activates)
• BioCarta hypoxia and p53 in the cardiovascular system: TFIID/RPA/JNK/p300/p53 complex (TAF1-RPA1-MAPK8-EP300-TP53) → GADD45A (transcription, activates)
• BioCarta hypoxia and p53 in the cardiovascular system: TFIID/RPA/JNK/p300/p53 complex (TAF1-RPA1-MAPK8-EP300-TP53) → FHL2 (transcription, activates)
• BioCarta cell cycle: g2/m checkpoint: p53 (TP53) → p300 (EP300) (transcription, activates)
• BioCarta hypoxia and p53 in the cardiovascular system: TFIID/RPA/JNK/p300/p53 complex (TAF1-RPA1-MAPK8-EP300-TP53) → p21 (CDKN1A) (transcription, activates)
• BioCarta hypoxia and p53 in the cardiovascular system: TFIID/RPA/JNK/p300/p53 complex (TAF1-RPA1-MAPK8-EP300-TP53) → IGFBP3 (transcription, activates)
• BioCarta cell cycle: g2/m checkpoint: p53 (TP53) → p300 (EP300) (transcription, activates)
• BioCarta hypoxia and p53 in the cardiovascular system: TFIID/RPA/JNK/p300/p53 complex (TAF1-RPA1-MAPK8-EP300-TP53) → p53 (TP53) (modification, collaborate)
• BioCarta hypoxia and p53 in the cardiovascular system: TFIID/RPA/JNK/p300/p53 complex (TAF1-RPA1-MAPK8-EP300-TP53) → TFIID/RPA/JNK/p300 complex (TAF1-RPA1-MAPK8-EP300) (modification, collaborate)
  
• BioCarta hypoxia and p53 in the cardiovascular system: p53 (TP53) → TFIID/RPA/JNK/p300 complex (TAF1-RPA1-MAPK8-EP300) (modification, collaborate)
  
• KEGG Cell cycle: CREBBP/EP300 → TP53 (protein-protein, activation)
• KEGG Prostate cancer: CREBBP/EP300 → TP53 (protein-protein, missing interaction)
• NCI Pathway Database Direct p53 effectors: GCN5-L/ADA2B/TAF9 complex (KAT2A-TADA2B-TAF9) → p53/Cbp/p300/CARM1/PRMT1 (tetramer) complex (TP53-EP300_CREBBP-CARM1-PRMT1) (transcription, activates)
  An et al., Cell 2004, Gamper et al., Mol Cell Biol 2008
  Evidence: mutant phenotype, reporter gene, physical interaction
• NCI Pathway Database Direct p53 effectors: nucleus (EP300/CREBBP) → p53 (tetramer) complex (TP53) (transcription, activates)
  Fei et al., Cancer Cell 2004*
  Evidence: mutant phenotype, reporter gene, physical interaction
• NCI Pathway Database Direct p53 effectors: nucleus (EP300/CREBBP) → p53 (tetramer) complex (TP53) (transcription, activates)
  Saifudeen et al., J Biol Chem 2000*
  Evidence: mutant phenotype, reporter gene, physical interaction, other species
• NCI Pathway Database p53 pathway: p53 (TP53) → MDM2/UBCH5/Cbp/p300 complex (MDM2-UBE2D1-EP300_CREBBP) (proteasomal ubiquitin-dependent protein catabolic process, collaborate)
  Rodriguez et al., Mol Cell Biol 2000, Mayo et al., Proc Natl Acad Sci U S A 2001, Zhou et al., Nat Cell Biol 2001, Li et al., Science 2003, Ferreon et al., Proc Natl Acad Sci U S A 2009, Siepe et al., Nat Cell Biol 2009, Haupt et al., Nature 1997
  Evidence: mutant phenotype, assay, physical interaction
• NCI Pathway Database p53 pathway: p53/PIN1 complex (TP53-PIN1) → MDM2/UBCH5/Cbp/p300 complex (MDM2-UBE2D1-EP300_CREBBP) (proteasomal ubiquitin-dependent protein catabolic process, inhibits)
  Rodriguez et al., Mol Cell Biol 2000, Mayo et al., Proc Natl Acad Sci U S A 2001, Zhou et al., Nat Cell Biol 2001, Li et al., Science 2003, Ferreon et al., Proc Natl Acad Sci U S A 2009, Siepe et al., Nat Cell Biol 2009, Haupt et al., Nature 1997
  Evidence: mutant phenotype, assay, physical interaction
• NCI Pathway Database p53 pathway: Cbp/p300/SKP2 complex (EP300_CREBBP-SKP2) → p53 (tetramer) complex (TP53) (modification, inhibits)
  Tang et al., Cell 2008
  Evidence: mutant phenotype, assay
• NCI Pathway Database p53 pathway: nucleus (EP300/CREBBP) → p53 (tetramer) complex (TP53) (modification, activates)
  Tang et al., Cell 2008
  Evidence: mutant phenotype, assay
• NCI Pathway Database Direct p53 effectors: p53 (tetramer) complex (TP53) → Cbp/p300/JMY complex (EP300_CREBBP-JMY) (transcription, activates)
  Shikama et al., Mol Cell 1999, Thornborrow et al., J Biol Chem 2001, Thornborrow et al., Oncogene 2002, Hudson et al., J Biol Chem 2005, Sykes et al., Mol Cell 2006
  Evidence: mutant phenotype, reporter gene, physical interaction
• NCI Pathway Database Direct p53 effectors: PRMT1 (PRMT1) → p53/Cbp/p300/CARM1/PRMT1 (tetramer) complex (TP53-EP300_CREBBP-CARM1-PRMT1) (modification, collaborate)
  An et al., Cell 2004
  Evidence: mutant phenotype, physical interaction
• NCI Pathway Database Direct p53 effectors: p53/Cbp/p300/CARM1/PRMT1 (tetramer) complex (TP53-EP300_CREBBP-CARM1-PRMT1) → nucleus (EP300/CREBBP) (modification, collaborate) An et al., Cell 2004
  Evidence: mutant phenotype, physical interaction
• NCI Pathway Database Direct p53 effectors: p53/Cbp/p300/CARM1/PRMT1 (tetramer) complex (TP53-EP300_CREBBP-CARM1-PRMT1) → CARM1 (CARM1) (modification, collaborate) An et al., Cell 2004
  Evidence: mutant phenotype, physical interaction
• NCI Pathway Database Direct p53 effectors: p53/Cbp/p300/CARM1/PRMT1 (tetramer) complex (TP53-EP300_CREBBP-CARM1-PRMT1) → p53 (tetramer) complex (TP53) (modification, collaborate)
  An et al., Cell 2004
  Evidence: mutant phenotype, physical interaction
• NCI Pathway Database Direct p53 effectors: nucleus (EP300/CREBBP) → p53 (tetramer) complex (TP53) (modification, collaborate)
  An et al., Cell 2004
  Evidence: mutant phenotype, physical interaction
• WikiPathways Signaling Pathways in Glioblastoma: EP300 → TP53 (mim-stimulation)
• WikiPathways Cell Cycle: EP300 → TP53 (activation)

Protein-Protein interactions - manually collected from original source literature:

Studies that report less than 10 interactions are marked with *

• IRef Bind Interaction: EP300 — TP53 An et al., Cell 2004
• IRef Bind Interaction: EP300 — TP53 Zeng et al., Mol Cell Biol 2000
• IRef Bind Interaction: Complex of EP300-TP53 Thomas et al., Mol Cell 2005*
• IRef Bind Interaction: Complex of PRMT1-TP53-EP300 An et al., Cell 2004
• IRef Bind Interaction: Complex of EP300-CARM1-TP53 An et al., Cell 2004
• IRef Bind Interaction: Complex of TP53-EP300 Thomas et al., Mol Cell 2005*
• IRef Bind_translation Interaction: EP300 — TP53 (unspecified method) Zeng et al., Mol Cell Biol 2000
• IRef Bind_translation Interaction: EP300 — TP53 (experimental interaction detection) Yan et al., EMBO J 2005*
• IRef Bind_translation Interaction: EP300 — TP53 (affinity chromatography technology) An et al., Cell 2004
• IRef Bind_translation Interaction: EP300 — TP53 (coimmunoprecipitation) An et al., Cell 2004
• IRef Bind_translation Interaction: EP300 — TP53 (coimmunoprecipitation) Issaeva et al., Nat Med 2004*
• IRef Bind_translation Interaction: EP300 — TP53 (unspecified method) Issaeva et al., Nat Med 2004*
• IRef Biogrid Interaction: EP300 — TP53 (physical association, affinity chromatography technology) Li et al., Cancer Lett 2012*
• IRef Biogrid Interaction: EP300 — TP53 (physical association, affinity chromatography technology) Sen et al., J Biol Chem 2011*
• IRef Biogrid Interaction: EP300 — TP53 (physical association, affinity chromatography technology) Gillotin et al., Cell cycle (Georgetown, Tex.) 2010*
• IRef Biogrid Interaction: EP300 — TP53 (physical association, affinity chromatography technology) Issaeva et al., Nat Med 2004*
• IRef Biogrid Interaction: EP300 — TP53 (physical association, affinity chromatography technology) Dornan et al., Mol Cell Biol 2004*
• IRef Biogrid Interaction: EP300 — TP53 (physical association, affinity chromatography technology) Kitagawa et al., Mol Cell 2008*
• IRef Biogrid Interaction: EP300 — TP53 (direct interaction, enzymatic study) Sabbatini et al., DNA Cell Biol 2002*
• IRef Biogrid Interaction: EP300 — TP53 (colocalization, imaging technique) Lill et al., Nature 1997*
• IRef Biogrid Interaction: EP300 — TP53 (direct interaction, pull down) Burge et al., Proc Natl Acad Sci U S A 2009*
• IRef Biogrid Interaction: EP300 — TP53 (physical association, affinity chromatography technology) Zilfou et al., Mol Cell Biol 2001*
• IRef Biogrid Interaction: EP300 — TP53 (direct interaction, pull down) Feng et al., Structure 2009*
• IRef Biogrid Interaction: EP300 — TP53 (association, x-ray crystallography) Feng et al., Structure 2009*
• IRef Biogrid Interaction: EP300 — TP53 (direct interaction, enzymatic study) Dornan et al., Mol Cell Biol 2004*
• IRef Biogrid Interaction: EP300 — TP53 (physical association, affinity chromatography technology) Di Agostino et al., Cancer Cell 2006
• IRef Biogrid Interaction: EP300 — TP53 (association, x-ray crystallography) Wells et al., Proc Natl Acad Sci U S A 2008*
• IRef Biogrid Interaction: EP300 — TP53 (direct interaction, enzymatic study) Costanzo et al., Mol Cell 2002
• IRef Biogrid Interaction: EP300 — TP53 (direct interaction, enzymatic study) Fath et al., J Biol Chem 2006*
• IRef Biogrid Interaction: EP300 — TP53 (direct interaction, enzymatic study) Kobet et al., Proc Natl Acad Sci U S A 2000*
• IRef Biogrid Interaction: EP300 — TP53 (physical association, affinity chromatography technology) Borger et al., J Virol 2006*
• IRef Biogrid Interaction: EP300 — TP53 (physical association, affinity chromatography technology) Kumazawa et al., J Biol Chem 2011*
• IRef Biogrid Interaction: EP300 — TP53 (physical association, affinity chromatography technology) Cui et al., Oncogene 2014*
• IRef Biogrid Interaction: EP300 — TP53 (physical association, affinity chromatography technology) Lee et al., J Biol Chem 2013*
• IRef Biogrid Interaction: EP300 — TP53 (direct interaction, pull down) An et al., Cell 2004
• IRef Biogrid Interaction: EP300 — TP53 (direct interaction, enzymatic study) Livengood et al., J Biol Chem 2002*
• IRef Biogrid Interaction: EP300 — TP53 (direct interaction, pull down) Livengood et al., J Biol Chem 2002*
• IRef Biogrid Interaction: EP300 — TP53 (direct interaction, pull down) Grossman et al., Mol Cell 1998*
• IRef Biogrid Interaction: EP300 — TP53 (physical association, affinity chromatography technology) Grossman et al., Mol Cell 1998*
• IRef Biogrid Interaction: EP300 — TP53 (colocalization, biochemical) Grossman et al., Mol Cell 1998*
• IRef Biogrid Interaction: EP300 — TP53 (physical association, affinity chromatography technology) Wang et al., J Biol Chem 2008*
• IRef Biogrid Interaction: EP300 — TP53 (direct interaction, enzymatic study) Tang et al., Cell 2008
• IRef Biogrid Interaction: EP300 — TP53 (physical association, affinity chromatography technology) Valbuena et al., PloS one 2008*
• IRef Biogrid Interaction: EP300 — TP53 (direct interaction, enzymatic study) Shi et al., Proc Natl Acad Sci U S A 2009*
• IRef Biogrid Interaction: EP300 — TP53 (physical association, affinity chromatography technology) Vega et al., Mol Cell Biol 2004*
• IRef Biogrid Interaction: EP300 — TP53 (direct interaction, enzymatic study) Pedeux et al., Mol Cell Biol 2005*
• IRef Biogrid Interaction: EP300 — TP53 (physical association, affinity chromatography technology) Grönroos et al., Proc Natl Acad Sci U S A 2004*
• IRef Biogrid Interaction: EP300 — TP53 (direct interaction, unspecified method) Finlan et al., J Biol Chem 2004*
• IRef Biogrid Interaction: EP300 — TP53 (physical association, affinity chromatography technology) Roe et al., Mol Cell 2006*
• IRef Biogrid Interaction: EP300 — TP53 (physical association, affinity chromatography technology) Zhao et al., Mol Cell Biol 2006*
• IRef Biogrid Interaction: EP300 — TP53 (physical association, affinity chromatography technology) Pan et al., Proc Natl Acad Sci U S A 2009*
• IRef Biogrid Interaction: EP300 — TP53 (direct interaction, enzymatic study) Sekaric et al., Oncogene 2007*
• IRef Biogrid Interaction: EP300 — TP53 (direct interaction, enzymatic study) Grossman et al., Science 2003*
• IRef Biogrid Interaction: EP300 — TP53 (direct interaction, enzymatic study) Tang et al., Mol Cell 2006
• MIPS CORUM p300-MDM2-p53 protein complex: p300-MDM2-p53 protein complex complex (EP300-MDM2-TP53) Kobet et al., Proc Natl Acad Sci U S A 2000*
• IRef Corum Interaction: Complex of EP300-MDM2-TP53 (association, chromatography technology) Kobet et al., Proc Natl Acad Sci U S A 2000*
• IRef Hprd Interaction: Complex of ING2-EP300-TP53-EP300-ING2-TP53-EP300-ING2-TP53 (in vivo) Wang et al., FEBS Lett 2006*
• IRef Hprd Interaction: TP53 — EP300 (in vitro) Pastorcic et al., J Biol Chem 2000*, Bernat et al., J Gen Virol 2002*, Wang et al., J Biol Chem 2003*, Cesková et al., J Mol Biol 2006*, Gu et al., Nature 1997*, Gu et al., Cell 1997*, Sakaguchi et al., Genes Dev 1998*, Grossman et al., Mol Cell 1998*
• IRef Hprd Interaction: TP53 — EP300 (in vivo) Pastorcic et al., J Biol Chem 2000*, Bernat et al., J Gen Virol 2002*, Wang et al., J Biol Chem 2003*, Cesková et al., J Mol Biol 2006*, Gu et al., Nature 1997*, Gu et al., Cell 1997*, Sakaguchi et al., Genes Dev 1998*, Grossman et al., Mol Cell 1998*
• IRef Intact Interaction: Complex of TP53-EP300-PPP1R13L (association, anti bait coimmunoprecipitation) Gillotin et al., FEBS Lett 2011*
• IRef Intact Interaction: Complex of EP300-TP53BP2-TP53 (association, anti bait coimmunoprecipitation) Gillotin et al., FEBS Lett 2011*
• IRef Intact Interaction: Complex of PPP1R13B-TP53-EP300 (association, anti bait coimmunoprecipitation) Gillotin et al., FEBS Lett 2011*
• IRef Intact Interaction: Complex of EP300-TP53-CREBBP (association, pull down) Gu et al., Nature 1997*
• IRef Intact Interaction: Complex of MYBBP1A-TP53-EP300-MYBBP1A-TP53-EP300 (association, anti bait coimmunoprecipitation) Kumazawa et al., J Biol Chem 2011*
• IRef Intact Interaction: EP300 — TP53 (physical association, anti bait coimmunoprecipitation) Shikama et al., Mol Cell 1999
• IRef Intact Interaction: EP300 — TP53 (direct interaction, pull down) Bernat et al., J Gen Virol 2002*
• IRef Intact Interaction: EP300 — TP53 (physical association, anti bait coimmunoprecipitation) Vega et al., Mol Cell Biol 2004*
• IRef Intact Interaction: EP300 — TP53 (physical association, coimmunoprecipitation) Borger et al., J Virol 2006*
• IRef Intact Interaction: EP300 — TP53 (physical association, anti bait coimmunoprecipitation) Wang et al., FEBS Lett 2006*
• IRef Intact Interaction: EP300 — TP53 (direct interaction, anti bait coimmunoprecipitation) Wu et al., EMBO J 2009*
• IRef Intact Interaction: EP300 — TP53 (acetylation reaction, enzymatic study) Tang et al., Cell 2008
• IRef Intact Interaction: EP300 — TP53 (physical association, anti bait coimmunoprecipitation) Mantovani et al., Nature structural & molecular biology 2007*
• IRef Intact Interaction: EP300 — TP53 (direct interaction, atomic force microscopy) Banerjee et al., FEBS Lett 2012*
• IRef Mppi Interaction: EP300 — TP53 (copurification) Zeng et al., Mol Cell Biol 2000
• IRef Ophid Interaction: EP300 — TP53 (aggregation, interologs mapping) Brown et al., Bioinformatics 2005

Text-mined interactions from Literome

Grossman et al., Eur J Biochem 2001 : p300/CBP/p53 interaction and regulation of the p53 response ... Through physical interaction with p53, p300/CBP can both positively and negatively regulate p53 transactivation, as well as p53 protein turnover depending on cellular context and environmental stimuli, such as DNA damage
Sabbatini et al., DNA Cell Biol 2002 : We demonstrate that MDMX dramatically inhibits the acetylation of p53 induced by both endogenous and ectopically expressed p300/CBP
Deng et al., Cancer Res 2005 (Cell Transformation, Neoplastic) : We further showed that p300/CBP were essential for ras induced p53 activity, providing a potential mechanism underlying the important role of p300/CBP in senescence
Li et al., Biochem Biophys Res Commun 2007 : ZNF307 might suppress p53-p21 pathway through activating MDM2 and EP300 expression and inducing p53 degradation
Kim et al., PloS one 2009 : Suppression of p300 histone acetyltransferase (p300HAT) activity by the p300HAT inhibitor anacardic acid ( AA ) or by down-regulation of p300 by siRNA prevented UV-induced MMP-1 expression and inhibited UV-enhanced gamma-H2AX, p53 level, and acetyl-H3
Sang et al., J Cell Biochem 1997 : Our data suggest that p300/CBP and TBP but not the pocket proteins, pRb, p107, and pRb2/p130 are functional targets of E1A in transcriptional regulation and that p53 transactivation requires the function of the p300/TBP/TFIIB complex, thus delineating a new pathway by which E1A may exert its transforming activity
Ravi et al., Cancer Res 1998 : p53 dependent transactivation and transrepression require its interaction with p300/CBP , a coactivator that also interacts with the RelA subunit of nuclear factor-kappaB